GlassScriptPhysician profile
Scott A Strelow
NPI 1043214315
$4,928.98
in general payments reported to CMS, 2019-2025
22 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $185 · 2021: $79.08 · 2022: $521 · 2023: $300 · 2024: $2,831 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679 · Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
| Food and Beverage | $968.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,861.38 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished), Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $563.18 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Allergan, INC. | $229.57 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $227.69 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $177.58 | 2022-2025 | Miebo, Xiidra |
| Biotissue Holdings INC. | $153.95 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $108.45 | 2020 | |
| Abbvie INC. | $107.73 | 2022 | |
| Dompe US, INC. | $96.29 | 2019-2025 | Oxervate |
| Mallinckrodt Enterprises LLC | $80.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.13 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $48.18 | 2021-2025 | |
| Shire North American Group INC | $32.73 | 2019 | |
| Rayner Intraocular Lenses Limited | $31.32 | 2024 | Omidria |
| Omeros Corporation | $21.83 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $19.27 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.43 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.05 | 2022 | |
| Ocular Therapeutix, INC. | $14.81 | 2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $14.36 | 2019 | |
| Amgen INC. | $13.93 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Strelow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.